

In the Claims:

✓
Please amend claims 1, 5-9 as follows, and cancel claims 10-11.

1. (currently amended) A pharmaceutical formulation comprising a
~~eytoprotective cytoprotection effective dose of a compound~~, comprising: a polycyclic
compound optionally having ~~two, three or four carbon rings~~, a four ring estrogen
structure ~~the compound also~~ having a first end and a second end wherein a phenol group
is located at the first end and a ~~terminal~~ D carbon ring is located at the second end, the
~~terminal~~ D carbon ring having an alkyl ether functional group on carbon 17 thereof, the
alkyl portion of which ~~having a formula C_nH_{2n+2} wherein n is at least 3 and less than 20~~ is
any of a long chain saturated alkyl, a long chain unsaturated alkyl, or a cycloalkyl group.

2-4. (cancelled)

B 1
5. (currently amended) A ~~eytoprotective compound~~ pharmaceutical formulation
to claim ~~[[4]]~~ 1, wherein the alkyl ether functional group is in an orientation selected
from the group consisting of an alpha or beta isomeric orientation on the carbon.

6. (currently amended) A ~~eytoprotective compound~~, pharmaceutical formulation
according to claim 1, wherein the alkyl group in the alkyl ether functional ~~is selected~~
~~from a long chain saturated alkyl group, long chain unsaturated alkyl group and a cyclo~~
~~alkyl group~~ is characterized by the formula of $C_nH_{(2n+1)}$ wherein n is at least 3 and less
than 20.

7. (currently amended) A ~~eytoprotective compound~~ pharmaceutical formulation
according to claim ~~[[4]]~~ 1, comprising: a 17-butoxyestra 1,3,5(10) triene-3-ol.

8. (currently amended) A ~~eytoprotective compound~~, pharmaceutical formulation
according to claim ~~[[4]]~~ 1, comprising: a 17-hexyloxyestra-1, 3,5(10)-triene-3-ol.

9. (currently amended) A ~~eytoprotective compound~~ pharmaceutical formulation
according to claim ~~[[4]]~~ 1, comprising: a 17- octyloxyestra-1, 3,5(10)-triene-3-ol.

10-11. (cancelled)